Characterization and potential clinical applications of autoantibodies against cytokines

Carina de Lemos Rieper; Pia Galle; Morten Bagge Hansen

doi:10.1016/j.cytogfr.2009.01.003

Characterization and potential clinical applications of autoantibodies against cytokines

Carina de Lemos Rieper, Pia Galle, Morten Bagge Hansen

20 Citations (Scopus)

Abstract

Autoantibodies recognizing cytokines arise in certain patients during the course of therapy with recombinant cytokines, although they may arise spontaneously as well. They are typically high avidity and in vitro neutralizing IgG antibodies present in picomolar to nanomolar concentrations. Methodology is therefore critical. Quantitative studies based on sound methodology strongly indicate that nanomolar levels of cytokine autoantibodies are likely to be involved in a number of "new" syndromes such as acquired immune deficiencies, lung diseases, and certain age-related manifestations. There are many ways in which the autoantibodies could be naturally induced, and they have been experimentally induced with ease. Therefore, a new therapeutic concept of inducing cytokine autoantibodies via anti-cytokine vaccination is currently rapidly emerging.

Original language	English
Journal	Cytokine & Growth Factor Reviews
Volume	20
Issue number	1
Pages (from-to)	61-75
Number of pages	14
ISSN	1359-6101
DOIs	https://doi.org/10.1016/j.cytogfr.2009.01.003
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cytogfr.2009.01.003

Cite this

@article{0b1dfb906a4b11df928f000ea68e967b,

title = "Characterization and potential clinical applications of autoantibodies against cytokines",

abstract = "Autoantibodies recognizing cytokines arise in certain patients during the course of therapy with recombinant cytokines, although they may arise spontaneously as well. They are typically high avidity and in vitro neutralizing IgG antibodies present in picomolar to nanomolar concentrations. Methodology is therefore critical. Quantitative studies based on sound methodology strongly indicate that nanomolar levels of cytokine autoantibodies are likely to be involved in a number of {"}new{"} syndromes such as acquired immune deficiencies, lung diseases, and certain age-related manifestations. There are many ways in which the autoantibodies could be naturally induced, and they have been experimentally induced with ease. Therefore, a new therapeutic concept of inducing cytokine autoantibodies via anti-cytokine vaccination is currently rapidly emerging.",

author = "{de Lemos Rieper}, Carina and Pia Galle and Hansen, {Morten Bagge}",

note = "Keywords: Allergy and Immunology; Animals; Autoantibodies; Autoimmunity; Cytokines; Humans; Immune Tolerance; Immunoglobulin G; Immunoglobulins, Intravenous; Immunologic Deficiency Syndromes; Immunologic Factors; Models, Biological; Protein Binding",

year = "2009",

doi = "10.1016/j.cytogfr.2009.01.003",

language = "English",

volume = "20",

pages = "61--75",

journal = "Cytokine & Growth Factor Reviews",

issn = "1359-6101",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Characterization and potential clinical applications of autoantibodies against cytokines

AU - de Lemos Rieper, Carina

AU - Galle, Pia

AU - Hansen, Morten Bagge

N1 - Keywords: Allergy and Immunology; Animals; Autoantibodies; Autoimmunity; Cytokines; Humans; Immune Tolerance; Immunoglobulin G; Immunoglobulins, Intravenous; Immunologic Deficiency Syndromes; Immunologic Factors; Models, Biological; Protein Binding

PY - 2009

Y1 - 2009

N2 - Autoantibodies recognizing cytokines arise in certain patients during the course of therapy with recombinant cytokines, although they may arise spontaneously as well. They are typically high avidity and in vitro neutralizing IgG antibodies present in picomolar to nanomolar concentrations. Methodology is therefore critical. Quantitative studies based on sound methodology strongly indicate that nanomolar levels of cytokine autoantibodies are likely to be involved in a number of "new" syndromes such as acquired immune deficiencies, lung diseases, and certain age-related manifestations. There are many ways in which the autoantibodies could be naturally induced, and they have been experimentally induced with ease. Therefore, a new therapeutic concept of inducing cytokine autoantibodies via anti-cytokine vaccination is currently rapidly emerging.

AB - Autoantibodies recognizing cytokines arise in certain patients during the course of therapy with recombinant cytokines, although they may arise spontaneously as well. They are typically high avidity and in vitro neutralizing IgG antibodies present in picomolar to nanomolar concentrations. Methodology is therefore critical. Quantitative studies based on sound methodology strongly indicate that nanomolar levels of cytokine autoantibodies are likely to be involved in a number of "new" syndromes such as acquired immune deficiencies, lung diseases, and certain age-related manifestations. There are many ways in which the autoantibodies could be naturally induced, and they have been experimentally induced with ease. Therefore, a new therapeutic concept of inducing cytokine autoantibodies via anti-cytokine vaccination is currently rapidly emerging.

U2 - 10.1016/j.cytogfr.2009.01.003

DO - 10.1016/j.cytogfr.2009.01.003

M3 - Journal article

C2 - 19213592

SN - 1359-6101

VL - 20

SP - 61

EP - 75

JO - Cytokine & Growth Factor Reviews

JF - Cytokine & Growth Factor Reviews

IS - 1

ER -

Characterization and potential clinical applications of autoantibodies against cytokines

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this